Stock Price Quote

ONESOURCE SPECIALTY PHARMA LTD.

NSE : ONESOURCEBSE : 544292ISIN CODE : INE013P01021Industry : Pharmaceuticals & DrugsHouse : Private
BSE1444.35-16.65 (-1.14 %)
PREV CLOSE ( ) 1461.00
OPEN PRICE ( ) 1461.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1442.00 (50)
VOLUME 10730
TODAY'S LOW / HIGH ( )1424.70 1461.55
52 WK LOW / HIGH ( )1075 1924
NSE1442.40-16.7 (-1.14 %)
PREV CLOSE( ) 1459.10
OPEN PRICE ( ) 1459.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1442.40 (841)
VOLUME 303380
TODAY'S LOW / HIGH( ) 1423.90 1460.00
52 WK LOW / HIGH ( )1057 1925
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-06 2007
Management Info
Arun Kumar - Chairman Neeraj Sharma - Managing Director
Registered Office

Address Unit No. 902, Cyber One,Plot No - 4 & 6,Sector 30 A, Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022 2789 2924

Email info@onesourcecdmo.com

Website www.onesourcecdmo.com

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE, NSE

NEWS

21Jul Onesource Specialty Pharma submits ana
Onesource Specialty Pharma has informed that the Company has scheduled i..
14Jul OneSource Specialty Pharma, Formycon p
OneSource Specialty Pharma has entered into a strategic manufacturing pa..
14Jul OneSource Specialty Pharma informs ab
OneSource Specialty Pharma has informed that it enclosed Press Release i..
02Jul USFDA completes cGMP inspection at One
The United States Food and Drug Administration (USFDA) has conducted a r..
16May Onesource Specialty Pharma informs abo
Onesource Specialty Pharma has informed that the Government of Karnataka..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit512.25212.1
Gross Profit 512.25 212.1
Operating Profit 1179.192840.01
Net Sales 4464.7114053.81

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26346.00 (2.56%)
M.Cap ( in Cr)55983.41
Symbiotec Pharmalab (BSE)
peergroup  1251.60 (6.69%)
M.Cap ( in Cr)8042.29
Astrazeneca Pharma (BSE)
peergroup  5943.50 (0.96%)
M.Cap ( in Cr)14858.75
Sudeep Pharma (BSE)
peergroup  1056.75 (4.20%)
M.Cap ( in Cr)11935.85
CORONA Remedies (BSE)
peergroup  2060.65 (1.83%)
M.Cap ( in Cr)12602.95

Shareholding Pattern

PROMOTERS 30.48%
NON-INSTITUTION 26.94%
FI/BANKS/INSURANCE 2.86%
MUTUAL FUNDS/UTI 12.98%
GOVERNMENT 0%
FII 0%

About Onesource Specialty Pharma Ltd.

Onesource Specialty Pharma Ltd. was incorporated in the year 2007. Its today's share price is 1444.35. Its current market capitalisation stands at Rs 16562.91 Cr. In the latest quarter, company has reported Gross Sales of Rs. 14184.64 Cr and Total Income of Rs.14523.26 Cr. The company's management includes Neeraj Sharma, Bharat D Shah, Vijay Karwal, Colin Michael Bond, Rashmi Barbhaiya, Claudio Albrecht, Debarati Sen, Arun Kumar, A Trisha.

It is listed on the BSE with a BSE Code of 544292 , NSE with an NSE Symbol of ONESOURCE and ISIN of INE013P01021. It's Registered office is at Unit No. 902, Cyber One,Plot No - 4 & 6,Sector 30 A, VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.